Suicidality in clozapine-treated patients with schizophrenia: Role of obsessive-compulsive symptoms

Psychiatry Research

Volumn 230, Issue 1, 2015, Pages 50-55

  Szmulewicz, Alejandro G ^a   Smith, José M ^a   Valerio, Marina P ^a  

^a Hospital Alvear   (Argentina)

Author keywords

Clozapine; Obsessive compulsive disorder; Schizo OCD Suicide; Schizophrenia; Suicide attempt

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDE; SUICIDE ATTEMPT; TREND STUDY; YALE BROWN OBSESSIVE COMPULSIVE SCALE; CROSS-SECTIONAL STUDY; OBSESSIVE-COMPULSIVE DISORDER; RETROSPECTIVE STUDY; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PREVALENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SUICIDAL IDEATION; SUICIDE; SUICIDE, ATTEMPTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942297225     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.07.089     Document Type: Article

References (55)

1. Achim A.M., Maziade M., Raymond E., Olivier D., Mérette C., Roy M.A. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr. Bull. 2011, 37(4):811-821.
2. Addington D., Addington J., Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr. Res. 1994, 11(3):239-244.
3. Bleakley S., Brown D., Taylor D. Does clozapine cause or worsen obsessive compulsive symptoms? An analysis and literature review. Ther. Adv. Psychopharmacol. 2011, 1(6):181-188.
4. Boyette, Swets L., Meijer M., Wouters C., L, G R O U P Authors Factor structure of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) in a large sample of patients with schizophrenia or related disorders and comorbid obsessive-compulsive symptoms. Psychiatry Res. 2011, 186(2-3):409-413. Apr 30.
5. Braga R.J., Mendlowicz M.V., Marrocos R.P., Figueira I.L. Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J. Psychiatry Res. 2005, 39:409-414.
6. Cederlöf M., Lichtenstein P., Larsson H., et al. Obsessive-compulsive disorder, psychosis, and bipolarity: a longitudinal cohort and multigenerational family study. Schizophr. Bull. 2014, 10.1093/schbul/sbu169.
7. Cosoff S.J., Hafner R.J. The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder and bipolar disorder. Aust. NZ J. Psychiatry 1998, 32:67-72.
8. de Haan L., Oekeneva A., Van Amelsvoort T., Linszen D. Obsessive-compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders. Eur. Psychiatry J. Assoc. Eur. Psychiatry 2004, 19(8):524.
9. de Haan L., Hoogenboom B., Beuk N., van Amelsvoort T., Linszen D. Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders. Can. J. Psychiatry 2005, 50(9):519-524. Aug.
10. de Haan L., Hoogeboom B., Beuk N., Wouters L., Dingemans P.M., Linszen D.H. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacol. Bull. 2006, 39(1):25-30.
11. de Haan L., Sterk B., Wouters L., Linszen D.H. The 5-year course of obsessive- compulsive symptoms and obsessive-compulsive disorder in first episode schizophrenia and related disorders. Schizophr. Bull. 2013, 39(1):151-160. Jan.
12. Obsessive-compulsive symptoms in schizophrenia 2015, Springer International Publishing, Switzerland. L. de Haan, F. Schirmbeck, M. Zink (Eds.).
13. Dodt J.E., Byerly M.J., Cuadros C., Christensen R.C. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline. Am. J. Psychiatry 1997, 154(4):582.
14. Ertugrul A., Anil Yagcioglu A.E., Eni N., Yazici K.M. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci. 2005, 59(2):219-222.
15. Faragian S., Fuchs C., Pashinian A., Weizman R., Weizman A., Poyurovsky M. Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder. Psychiatry Res. 2012, 197(1-2):19-22. , 10.1016/j.psychres.2012.02.024.
16. Fonseka T.M., Richter M.A., Muller D.J. Second generation antipsychotic-induced Obsessive-Compulsive Symptoms in Schizophrenia: a review of the experimental literature. Curr. Psychiatry Rep. 2014, 16:510.
17. Hagen K., Hansen B., Joa I., Larsen T.K. Prevalence and clinical characteristics of patients with obsessive-compulsive disorder in first-episode psychosis. BMC Psychiatry 2013, 30(13):156.
18. Inskip H.M., Harris E.C., Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br. J. Psychiatry 1998, 172:35-37.
19. Kapur S., Zipursky R.B., Remington G., Jones C., Dasilva J., Wilson A.A., Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry 1998, 155:921-928.
20. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 1999, 156:286-293.
21. Kapur S., Agid O., Mizrahi R., Li M. How antipsychotics work-from receptors to reality. NeuroRx. 2006, 3(1):10-21. Jan.
22. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry 2005, 62:593-602.
23. Keuneman R.J., Pokos V., Weerasundera R., Castle D.J. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Aust. N. Z. J. Psychiatry 2005, 39(5):336-343.
24. Lee J.L., Ma W.F., Yen W.J., Huang X.Y., Chiang L.C. Predicting the likelihood of suicide attempts for rural outpatients with schizophrenia. J. Clin. Nurs. 2012, 21(19-20):2896-2904. http://dx.doi.org/10.1111/j.1365-2702.2012.04206.x.
25. Lim M., Park D.Y., Kwon J.S., Joo Y.H., Hong K.S. Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J. Clin. Psychopharmacol. 2007, 27(6):712-713. Dec.
26. Lin S.K., Su S.F., Pan C.H. Higher plasma drug con- centration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther. Drug Monit. 2006, 28:303-307.
27. Lykouras L., Alevizos B., Michalopoulou P., Rabavilas A. Obsessive- compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(3):333-346. May.
28. Mahendran R., Liew E., Subramaniam M. De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. J. Clin. Psychiatry 2007, 68:542-545.
29. Meier S.M., Petersen L., Pedersen M.G., Arendt M.C., Nielsen P.R., Mattheisen M., Mors O., Mortensen P.B. Obsessive-compulsive disorder as a risk factor for schizophrenia: a nationwide study. JAMA Psychiatry 2014, 71(11):1215-1221.
30. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003, 60(1):82-91. Jan.
31. Miles C.P. Conditions predisposing to suicide: a review. J. Nerv. Ment. Dis. 1977, 164(4):231-246. Review.
32. Moore T.A., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., Crismon M.L., Essock S.M., Finnerty M., Marder S.R., Miller D.D., McEvoy J.P., Robinson D.G., Schooler N.R., Shon S.P., Stroup T.S., Miller A.L. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J. Clin. Psychiatry 2007, 68(11):1751-1762.
33. Mukhopadhaya K., Krishnaiah R., Taye T., Nigam A., Bailey A.J., Sivakumaran T., Fineberg N.A. Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern. J. Psychopharmacol. 2009, 23(1):6-13. Jan.
34. Niendam T.A., Berzak J., Cannon T.D., Bearden C.E. Obsessive compulsive symptoms in the psychosis prodrome: correlates of clinical and functional outcome. Schizophr. Res. 2009, 108:170-175.
35. Nordentoft M., Mortensen P.B., Pedersen C.B. Absolute risk of suicide after first hospital contact in mental disorder. Arch. Gen. Psychiatry. 2011, 68(10):1058-1064. http://dx.doi.org/10.1001/archgenpsychiatry.2011.113.
36. Owashi T., Ota A., Otsubo T., Susa Y., Kamijima K. Obsessive-compulsive disorder and obsessive-compulsive symptoms in Japanese inpatients with chronic schizophrenia-a possible schizophrenic subtype. Psychiatry Res. 2010, 179(3):241-246. Oct 30.
37. Palmer B.A., Pankratz V.S., Bostwick J.M. The lifetime risk of suicide in schizophrenia: a reexamination. Arch. Gen. Psychiatry 2005, 62(3):247-253.
38. Patel D.D., Laws K.R., Padhi A., Farrow J.M., Mukhopadhaya K., Krishnaiah R., Fineberg N.A. The neuropsychology of the schizo-obsessive subtype of schizophrenia: a new analysis. Psychol. Med. 2010, 40:921-933.
39. Poyurovsky M., Weizman A., Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 2004, 18(14):989-1010.
40. Rahman M.S., Grace J.J., Pato M.T., Priest B. Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior. Am. J. Psychiatry 1998, 155(11):1629-1630. Nov.
41. Ringbäck Weitoft G., Berglund M., Lindström E.A., Nilsson M., Salmi P., Rosén M. Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study. Pharmacoepidemiol. Drug Saf. 2014, 23(3):290-298. Mar.
42. Runeson B., Tidemalm D., Dahlin M., Lichtenstein P., Långström N. Method of attempted suicide as predictor of subsequent successful suicide: national long term cohort study. Br. Med. J. 2010, 341:c3222. http://dx.doi.org/10.1136/bmj.c3222.
43. Scheltema Beduin A.A., Swets M., Machielsen M., Korver N. Genetic Risk and Outcome of Psychosis Investigators. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. J. Clin. Psychiatry 2012, 73(11):1395-1402.
44. Schirmbeck F., Esslinger C., Rausch F., Englisch S., Meyer-Lindenberg A., Zink M. Antiserotonergic antipsychotics are associated with obsessive compulsive symptoms in schizophrenia. Psychol. Med. 2011, 41(11):2361-2373.
45. Schirmbeck F., Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr. Neuropharmacol. 2012, 10(1):88-95.
46. Schirmbeck F., Rausch F., Englisch S., Eifler S., Esslinger C., Meyer-Lindenberg A., Zink M. Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study. J. Psychopharmacol. 2013, 27:349-357.
47. Schirmbeck F., Zink M. Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front. Pharmacol. 2013, 9(4):99. Aug.
48. Schirmbeck F., Rausch F., Englisch S., Eifler S., Esslinger C., Meyer-Lindenberg A., Zink M. Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study. Schizophr. Bull. 2013, 39:1261-1271.
49. Scocco P., de Girolamo G., Vilagut G., Alonso J. Prevalence of suicide ideation, plans, and attempts and related risk factors in Italy: results from the European Study on the Epidemiology of Mental Disorders--World Mental Health study. Compr. Psychiatry 2008, 49(1):13-21.
50. Sevincok L., Akoglu A., Kokcu F. Suicidality in schizophrenic patients with and without obsessive-compulsive disorder. Schizophr. Res. 2007, 90:198-202.
51. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janays J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):S22-S33.
52. Swets M., Dekker J., van Emmerik-van Oortmerssen K., Smid G.E., Smit F., de Haan L., Schoevers R.A. The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. Schizophr. Res. 2014, 152(2-3):458-468.
53. Thomas K.L., Jiang Y., McCombs J.S. Clozapine revisited: impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid. Ann. Clin. Psychiatry 2015, 27(1):E1-E10. Feb 1.
54. Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN-11 study). Lancet 2009, 374:620-627.
55. Zink M., Schirmbeck F., Rausch F., Eifler S., Elkin H., Solojenkina X., Englisch S., Wagner M., Maier W., Lautenschlager M., Heinz A., Gudlowski Y., Janssen B., Gaebel W., Michel T.M., Schneider F., Lambert M., Naber D., Juckel G., Krueger-Oezguerdal S., Wobrock T., Hasan A., Riedel M., Müller H., Klosterkötter J., Bechdolf A. Obsessive-compulsive symptoms in at-risk mental states for psychosis: associations withclinical impairment and cognitive function. Acta Psychiatry Scand. 2014, 130(3):214-226.